Skip to main content
SpringerLink
Log in

Can Patients' Likelihood of Benefiting from Primary Chemotherapy for Breast Cancer Be Predicted Before Commencement of Treatment?

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose. Primary chemotherapy is commonly used in patients with breast cancer to downstage the primary tumour prior to surgery. There is a need to establish, prior to commencement of chemotherapy, predictors of clinical and pathological response, which may then be surrogate markers for patient survival and thus allow identification of patients who are most likely to benefit from such treatment.

Patients and methods. A total of 104 patients with large and locally advanced breast cancers received an anthracycline/docetaxel-based regimen prior to surgery. Immunohistochemistry was carried out on pre-treatment core biopsies of the tumour to detect hormone receptors (oestrogen-ER; progesterone-PR), a proliferation marker (MIB-1), the oncoprotein Bcl-2, an extracellular matrix degradation enzyme (cathepsin D), p53, and an oestrogen associated protein (pS2). Both clinical and pathological response were assessed following completion of chemotherapy.

Results. Patients whose tumours did not express oestrogen receptor (p= 0.02) or did not express Bcl-2 (p < 0.01) had a better pathological response in a univariate analysis. However, in a multivariate model, it was only the absence of detectable Bcl-2 protein that predicted a better pathological response (p= 0.001).

Conclusions. This study has identified that patients whose breast cancers are most likely to experience the greatest degree of tumour destruction by primary chemotherapy do not express either oestrogen receptors or Bcl-2. This may have important implications in the selection of patients with breast cancer for primary chemotherapy who are most likely to gain a survival benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fisher B, Brown A, Mamounas E et al.: Effect of pre-operative chemotherapy on the outcome in women with operable breast cancer. J Clin Oncol 16: 2272–2685, 1998

    Google Scholar 

  2. Ragaz J, Baird R, Rebbeck P et al.: Pre-operative versus post-operative chemotherapy for stage I-II breast cancer: long term analysis of British Columbia randomized trial. Proc Am Soc Clin Oncol 16: 142a, 1997 (Abstract)

    Google Scholar 

  3. Mauriac L, MacGrogan G, Avril A et al.: Neoadjuvant chemotherapy for breast cancers larger than 3 cms. A unicentre randomised trialwith a 124 month follow up. Ann Oncol 10: 47–52, 1999

    Google Scholar 

  4. Semiglazov VF, Topuzov EE, Bavli JL et al.: Primary chemotherapy and radiotherapy compared with primary chemotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 5: 591–595, 1994

    Google Scholar 

  5. Scholl SM, Fourquet A, Aselain B et al.: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial. Eur J Cancer 30A: 645–652, 1994

    Google Scholar 

  6. Makris A, Powles TJ, Ashley SE et al.: A reduction in the requirements for mastectomy in a randomised trial of neoadjuvant chemo-endocrine therapy in primary breast cancer. Ann Oncol 9: 1179–1194, 1998

    Google Scholar 

  7. Powles TJ, Hickish TF, Makris A et al.: A randomised trial of chemo-endocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13: 546–552, 1995

    Google Scholar 

  8. Miller AB, Hoogstraten B, Staquet MD et al.: Reporting results of cancer treatment. Cancer 47: 207–214, 1981

    Google Scholar 

  9. Brittenden J, Heys SD, Miller I et al.: Dietry supplemen-tation with L-arginine in patients with breast cancer (>4 cms) receiving multimodality treatment: report of a feasibility study. Br J Cancer 69: 918–921, 1994

    Google Scholar 

  10. Chollet P, Charrier S, Brain E et al.: Clinical and pathological responses to primary chemotherapy in oper-able breast cancer. Eur J Cancer 33: 862–866, 1997

    Google Scholar 

  11. Kuerer HM, Newman LA, Smith TL et al.: Clinical course of breast cancer patients with complete pathological primary tumour and lymph node response to doxorubicin based primary chemotherapy. J Clin Oncol 17: 460–469, 1999

    Google Scholar 

  12. Bonnadonna G, Valagussa P, Brambilla C et al.: Primary chemotherapy in operable breast cancer. Eight year expe-rience at the Milan Cancer Institute. J Clin Oncol 16: 93–100, 1998

    Google Scholar 

  13. Verril MW, Ashley SE, Walsh GA et al.: Pathological complete response in patients treated with neoadjuvant chemotherapy for operable breast cancer. Breast Cancer Res Treat 50: 328, 1998

    Google Scholar 

  14. MacGrogan G, Mauriac L, Durand M: Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erb-B2, MIB-1, pS2, GST. Br J Cancer 74: 1458–1465, 1996

    Google Scholar 

  15. Chang J, Powles TJ, Allred DC: Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17: 3058–3063, 1999

    Google Scholar 

  16. Sjostrom J, Blomquist C, Heikkila P et al.: Predictive value of p53, mdm-2, p21 and MIB-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 6: 3103–3010, 2000

    Google Scholar 

  17. Gonzalez-Vela MC, Garijo MF, Fernandez F et al.: MIB1 proliferation index in breast infiltrating carcinoma: com-parison with other proliferative markers and association with new biological prognostic factors. Histol Histopathol 16: 399–406, 2001

    Google Scholar 

  18. Lowe SW, Ruley HE, Jacks T et al.: P53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957–967, 1993

    Google Scholar 

  19. Levine A, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351: 453–456, 1991

    Google Scholar 

  20. Bonnetti A, Zaninelli M, Leone R et al.: Bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 4: 2331–2336, 1998

    Google Scholar 

  21. Ravaioli A, Bagli L, Zucchini A et al.: Prognosis and prediction of response in breast cancer: the current role of the main biological markers. Cell Prolif 31: 113–126, 1998

    Google Scholar 

  22. Bottini A, Beruti A, Bersiga A et al.: P53 but not Bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 6: 2751–2758, 2000

    Google Scholar 

  23. Clahsen PC, van de Velde CJ, Duval C et al.: p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node negative early breast cancer. J Clin Oncol 16: 470–479, 1998

    Google Scholar 

  24. Ferreira CG, Tolis C, Giaccone G: p53 and chemosensitivity. Ann Oncol 10: 1011–1021, 1999

    Google Scholar 

  25. Yang QF, Sakurai T, Yoshimura G: Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance anticancer drugs in breast carcinoma. Breast Cancer Res Treat 61: 211–216, 2000

    Google Scholar 

  26. Rayter Z: Steroid receptors in breast cancer. Br J Surg 78: 528–535, 1991

    Google Scholar 

  27. Kaufmann M: Review of known prognostic variables-recent results. Cancer Res 140: 77–87, 1996

    Google Scholar 

  28. Bundred BJ: Prognostic and predictive factors in breast cancer. Cancer Treat Rev 27: 137–142, 2001

    Google Scholar 

  29. MacGrogan G, Mauriac L, Durand M et al.: Primary chemotherapy in breast cancer: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erb-B2, MIB-1, pS2 and GST pi. Br J Cancer 74: 1458–1465, 1996

    Google Scholar 

  30. Takamura Y, Kobayashi H, Taguchi T et al.: Prediction of chemotherapeutic response by collagen gel droplet embed-ded culture drug sensitivity test in human breast cancers. Int J Cancer 98: 450–455, 2002

    Google Scholar 

  31. Jarvinen TA, Holli K, Kuukasjarvi T: Predictive value of topoisomerase I alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 77: 2267–2273, 1998

    Google Scholar 

  32. Jansen RL, Hupperets PS, Arends JW et al.: pS2 is an independent prognostic factor for post-relapse survival in primary breast cancer. Anticancer Res 18: 577–582, 1998

    Google Scholar 

  33. Miyoshi Y, Ando A, Takamura Y et al.: Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. Int J Cancer 97: 129–132, 2002

    Google Scholar 

  34. Egawa C, Motomura K, Miyoshi Y et al.: Increased expression of BRCA1 mRNA predicts favourable response to anthracyclin containing chemotherapy in breast cancers. Breast Cancer Res Treat 78: 45–50, 2003

    Google Scholar 

  35. Egawa C, Miyoshi Y, Takamura Y et al.: Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer 95: 255–259, 2001

    Google Scholar 

  36. Smith IC, Heys SD, Hutcheon AW et al.: Neo-adjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20: 1456–1466, 2002

    Google Scholar 

  37. Ogston KN, Miller I, Payne S et al.: A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and sur</del>vival. Breast 12: 320–327, 2003

    Google Scholar 

  38. Ellis PA, Smith IE, Detre S et al.: Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 48: 107–116, 1998

    Google Scholar 

  39. Bruce DM, Heys SD, Payne S, Miller ID, Eremin O: Male breast cancer: clinico-pathological features, immunocyto-chemical characteristics and prognosis. Eur J Surg Oncol 22: 42–46, 1996

    Google Scholar 

  40. Faneyte IF, Schrama JG, Peterse IL, Remijnse PL, Rode-nhuis S, van de Vijver MJ: Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 88: 406–412, 2003

    Google Scholar 

  41. Spyratos F, Ferro-Pous M, Trassard M et al.: Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cut-off value. Cancer 94: 2151–2159, 2002

    Google Scholar 

  42. Fisher B, Brown A, Mamounas E et al.: Effect of pre-operative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483–2493, 1997

    Google Scholar 

  43. Eltahir A, Heys SD, Hutcheon AW et al.: Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy. Am J Surg 175: 127–132, 1998

    Google Scholar 

  44. Sjostrom J: Predictive factors for response to chemotherapy in advanced breast cancer. Acta Oncol 41: 334–345, 2002

    Google Scholar 

  45. Stearns V, Singh B, Tsangaris T et al.: A prospective randomised pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 9: 124–133, 2003

    Google Scholar 

  46. Frassoldati A, Adami F, Banzi C et al.: Changes of biological features in breast cancer cells determined by primary chemotherapy. Breast Cancer Res Treat 44: 185–192, 1997

    Google Scholar 

  47. Makris A, Powles TJ, Dowsett M et al.: Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 3: 593–600

  48. Van Poznak C, Tan L, Panageas KS et al.: Asessment of molecular markers of clinical sensitivity to single agent taxane therapy for metastatic breast cancer. J Clin Oncol 20: 2319–2326, 2002

    Google Scholar 

  49. Sjostrom J, Colan J, von Boguslawski K et al.: C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer. Eur J Cancer 38: 535–542, 2002

    Google Scholar 

  50. Hamilton A, Larsimont D, Paridaens R et al.: A study of the value of p53, Her2 and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. Clin Breast Cancer 1: 233–240, 2000

    Google Scholar 

  51. Buchholz TA, Davis DW, McConkey DJ et al.: Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J 9: 33–41, 2003

    Google Scholar 

  52. Chang JC, Wooten EC, Tsmeizon et al.: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362: 362–369, 2003

    Google Scholar 

  53. Pusztai L, Ayers M, Simmans FW et al.: Emerging science: prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. Proc ASCO 22: 1, 2003

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University of Aberdeen, Medical School, Foresterhill, Aberdeen, AB25 2ZD, UK

    Keith N. Ogston, Andrew C. Schofield & Steven D. Heys

  2. Department of Pathology, University of Aberdeen, UK

    Iain D. Miller & Simon Payne

  3. Department of Molecular and Cell Biology, University of Aberdeen, UK

    Andrew C. Schofield, Andreas Spyrantis & Eleni Pavlidou

  4. Department of Oncology, Grampian University Hospitals NHS Trust, Aberdeen, UK

    Tarun K. Sarkar & Andrew W. Hutcheon

Authors
  1. Keith N. Ogston
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Iain D. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew C. Schofield
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andreas Spyrantis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eleni Pavlidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tarun K. Sarkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Andrew W. Hutcheon
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Simon Payne
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Steven D. Heys
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven D. Heys.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ogston, K.N., Miller, I.D., Schofield, A.C. et al. Can Patients' Likelihood of Benefiting from Primary Chemotherapy for Breast Cancer Be Predicted Before Commencement of Treatment?. Breast Cancer Res Treat 86, 181–189 (2004). https://doi.org/10.1023/B:BREA.0000032986.00879.d7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:BREA.0000032986.00879.d7

Search

Navigation